Aims Therapeutic options for patients with recurrent cardiac ischemia after coronary artery bypass surgery may be limited and some patients may be considered nonrevascularizable. To further the understanding of this patient cohort, we performed a population-based study of post-coronary bypass patients who developed recurrent angina.
Introduction
Coronary artery disease (CAD) is a leading cause of death in the United States and is responsible for up to 700 000 deaths per year [1] . Ongoing advances in molecular and cellular biology have led to new approaches being developed to limit cardiac ischemia. These new approaches, which include gene and cell delivery as well as novel mechanical approaches, are generally studied in a population that is considered to be not amenable to other conventional treatment modalities. The majority of these patients have already had coronary artery bypass grafting (CABG) and many suffer from refractory angina. Additional therapies such as percutaneous coronary intervention (PCI) or additional CABG are often unable to be offered to these patients in spite of ongoing angina. The decision to not pursue further therapies is complex and includes multiple patient-specific characteristics as well as physician-specific factors, many of which are nonquantifiable. Patients with refractory angina who have exhausted most therapeutic options comprise a growing clinical entity and a therapeutic dilemma. For this study, we define nonrevascularizable coronary disease after CABG as patients having ongoing angina despite optimal medical therapy after CABG deemed unamenable to further revascularization by conventional surgical or percutaneous means.
Currently, few data are available on the number of nonrevascularizable patients. Data from the Third National Health and Nutrition Examination Survey in 1994 estimated 300 000-900 000 patients in the United States have refractory angina and suggested that 25 000-75 000 new cases are diagnosed annually [2] . These figures, despite being out of date, are still quoted with respect to statistics regarding refractory angina patients from the American College of Cardiology and American Heart Association at present [3] . Mukherjee et al. [4] estimated that 100 000-200 000 patients per year may be eligible for new methods of revascularization based on estimates from a tertiary referral practice. Populationbased data estimating the true incidence of nonrevascularizable CAD are unavailable. The demographics of earlier clinical studies of nonrevascularizable or the so-called 'no option' patients suggest that the majority (up to 92%) of nonrevascularizable angina cases have had previous CABG [5, 6] .
This study was performed to provide an understanding of this nonrevascularizable group of patients in terms of demographics, incidence, and outcomes. We endeavored to determine a population-based incidence of nonrevascularizable CAD concentrating on post-CABG patients using the resources of the Olmsted County database, Rochester Epidemiology Project, and the Mayo Clinic Cardiac Catheterization Laboratory. Patients who underwent coronary and bypass graft angiography for angina from Olmsted County, Minnesota, from 2001 to 2005, were studied.
Methods
The study was conducted in Olmsted County, Minnesota. The Mayo Clinic and the Olmsted Medical Center provided almost all medical care for the local population. These institutions have accumulated comprehensive records that contain high-quality information from all healthcare encounters including laboratory results, pathology reports, and autopsy results. The Rochester Epidemiology Project maintains extensive indexes based on clinical and histological diagnoses and surgical procedures for all providers of care to county residents, and all records are linked from all sources of care for this population. The study was approved by the Mayo Foundation Institutional Review Board. Patients refusing permission for medical records research were excluded as required by state of Minnesota statute (n = 44).
Clinical and angiographic records were searched using administrative and clinical databases to identify all Olmsted County patients with earlier CABG that underwent coronary and bypass graft angiography from 1 January 2001 to 31 December 2005. Complete medical records from consecutive post-coronary bypass Olmsted County patients who underwent angiography from 1 January 2001 to 31 December 2005 were reviewed to determine the clinical indication for coronary angiography, clinical management decisions, and patient demographics. Standard care for these patients involved coordinated care between cardiologists and cardiac surgeons. As all patients included in the study were Olmsted County residents, prospective follow-up was performed in all patients until 1 March 2008, using the resources of the Rochester Epidemiology Project and the Mayo Clinic electronic medical records.
Patient characteristics recorded included the diagnoses of diabetes (types 1 and 2), systemic hypertension, current cigarette smoking, earlier PCI, or earlier redo coronary bypass grafting. Chronic renal impairment was determined by previous established diagnosis, creatinine clearance less than 60 ml/min, or ongoing hemodialysis.
Cineangiograms from consecutive post-coronary bypass Olmsted County patients with angina during the period 2001-2005 were reviewed. This angiographic review was performed by two experienced interventional cardiologists to determine whether further revascularization was technically possible, either percutaneously or through coronary artery bypass surgery, and to assess the angiographic reasons for nonrevascularization.
Statistical analysis
Continuous variables are presented as the mean ± standard deviation; discrete variables are reported as the frequency (percentage). Survival rates were estimated using Kaplan-Meier methods and are reported as a percentage. Group comparisons are tested using Student's t-test, Pearson's w 2 test, and the log-rank test, respectively. Cox proportional hazards models were used to calculate hazard ratios and their 95% confidence intervals (CIs). The incidence of nonrevascularizable CAD in the post-bypass population was calculated using the 92 cases (angiographically truly nonrevascularizable) and 170 cases (not revascularized further) as the numerator and the Olmsted County population as the denominator. The Olmsted County population was calculated based on yearly US census projections from the 2000 census. The rates were adjusted directly to the sex and age distributions from the US 2000 white population. CIs for the point estimates are based on a Poisson model [7] . All data were stored and analyzed using JMP software (SAS Institute, Cary, North Carolina, USA).
Results
From 2001 to 2005 inclusive, a total of 545 Olmsted County residents underwent bypass graft angiography at the Mayo Clinic Catheterization Laboratory. Of these, 347 individual patients were referred with the clinical indication of angina. The remainder of the angiographic graft studies was performed for other indications such as preoperative assessment or evaluation of left ventricular dysfunction.
Baseline clinical characteristics
Baseline characteristics of the 347 post-coronary bypass patients who underwent graft studies for symptomatic angina are listed in Table 1 . The majority of these patients (91%) were in Canadian Cardiovascular Society angina class III/IV. These 347 patients had characteristics of a high-risk population: 69% were male, 37.5% had diabetes (types I and II), 36% had chronic renal impairment, 40% had had earlier PCI, and 6% had undergone a second coronary artery bypass procedure. The mean left ventricular ejection fraction of the population was 50 ± 12%.
Of the initial 347 patients, a clinical decision was made after angiography to revascularize 177 patients, whereas the remaining 170 patients were treated medically. Further revascularization was defined as any revascularization procedure, percutaneous or surgical, performed after the index coronary and bypass graft(s) angiography, and included 145 patients with PCI and 32 with CABG. Comparisons of baseline characteristics between those revascularized and those treated medically are listed in Table 2 . Both groups had a mean age of 72 years, and were predominantly male patients with no significant differences between groups in the incidence of diabetes mellitus, systemic hypertension, or chronic renal failure. However, the percentage of patients in the group that received further revascularization having had two or more coronary artery bypass graft operations was significantly higher (P = 0.03) than the group that did not undergo further revascularization.
The median duration of follow-up in both groups was 3.2 years (interquartile range 0.60-5.45 years). Estimated allcause mortality did not differ between the two groups (23.2% in the revascularized group and 31.1% for the group that did not undergo further revascularization) (P = 0.08). Using the log-rank test to compare these two Kaplan-Meier survival curves, no significant difference was found (P = 0.1, Fig. 1 ). In addition, no differences were demonstrated in terms of cardiac mortality (Fig. 2 ) between the groups. Multivariate analysis identified the presence of chronic renal failure, diabetes mellitus, and severe left ventricular dysfunction (left ventricular ejection fraction of less than or equal to 35%) were independent predictors of mortality ( Fig. 3 ). Lack of revascularization was not a predictor of mortality in this analysis. Taken together, these data do not provide support that revascularization improves mortality in this population.
Subgroup analysis
Angiographic analysis of the group that did not undergo further revascularization was performed by two experienced interventional cardiologists. It should be noted that all patients in this group had demonstrable ischemia on functional echocardiographic or nuclear studies. After detailed angiographic analysis, 92 patients were classified as being technically nonrevascularizable by conventional percutaneous or surgical means. The predominant (6) PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting. Not revascularized Revascularized Kaplan-Meier survival analysis: all-cause mortality. Kaplan-Meier survival analysis was performed on the group that did not receive further revascularization and the group that was revascularized further in terms of all-cause mortality. Using the log-rank P value to compare these curves. There was no significant difference between the two groups in terms of survival (P = 0.106).
reasons for nonrevascularizability included the presence of chronic total occlusions, degenerated saphenous vein grafts, and diffuse disease extending beyond the graft insertion ( Table 3 ). The remaining 78 patients in the group, despite suffering from angina and having proven functional ischemia, had adequately functioning grafts to all major epicardial territories making further PCI or surgical revascularization unnecessary. It is likely that these patients represented manifestations of microvascular CAD.
The all-cause mortality rate of this group of patients (n = 92) that were technically nonrevascularizable from a technical and angiographic point of view was 34.7%. The cardiac mortality rate was 21.7%. When compared with the revascularized group, there was no statistical difference in all-cause (P = 0.13) or cardiac mortality (P = 0.34).
Estimate of incidence of post-CABG nonrevascularizable coronary artery disease
The community-based nature of this study enabled us to estimate an incidence of nonrevascularizable CAD. The group of 92 patients with no revascularization potential (based on detailed angiographic analysis) and the group of 170 patients who did not receive further revascularization formed the basis of our estimates. Adjusting for age and sex for differences between the Olmsted County population and the US white 2000 population yields an annual incidence of postsurgical nonrevascularizable CAD of 17.9 per 100 000 (95% CI: 14.2-21.6) equating to 50 000 (95% CI: 40 000-61 000) nonrevascularizable angina cases per year with respect to the angiographically nonrevascularizable patient cohort. If all 170 patients who did not undergo further revascularization despite angina are included, this yields an annual incidence of postsurgical nonrevascularizable CAD of 33.2 per 100 000 (95% CI: 28.2-38.3) or approximately 93 000 (95% CI: 79 000-110 000) nonrevascularizable angina cases per year after bypass per year when adjusted to the US population as of 1 April 2000. Hence, our estimate of post-CABG nonrevascularizable CAD is between 50 000 and 93 000 patients per year.
Discussion
To effectively translate novel therapies to patients with advanced ischemic heart disease after CABG, the burden and outcomes of such patients must be defined. In this population-based study of patients with symptomatic angina referred for coronary angiography post-CABG, further revascularization did not reduce all-cause or cardiac mortality. Multivariate analysis identified diabetes, renal dysfunction, and severe reduction of left ventricular ejection fraction as predictors of mortality. Revascularized Kaplan-Meier survival analysis: cardiac mortality. Kaplan-Meier survival analysis was performed on the group that did not receive further revascularization and the group that was revascularized further in terms of cardiac mortality. Using the log-rank P value to compare these curves. There was no significant difference between the two groups in terms of survival (P = 0.312). These results must be considered in the translation of novel therapeutics, which might target ischemia.
Of those patients in this cohort treated medically, a nonrevascularizable group of 92 patients post-bypass based on angiographic analysis from Olmsted County over a 5-year period from 2001 to 2005 was defined. A further 78 patients who did not undergo further revascularization as all conduits to all major epicardial territories were patients still suffer from angina despite medical management. Adjusting for age and sex for differences between the Olmsted County population and the US white 2000 population yields a yearly incidence rate of nonrevascularizable CAD after bypass of 17.9 per 100 000 (95% CI: 14.2-21.6) to 33.2 per 100 000 (95% CI: 28.2-38.3). This incidence provides a population-based estimate of approximately 50 000 (95% CI: 40 000-61 000) to 93 000 (95% CI: 79 000-110 000) patients with nonrevascularizable angina after bypass per year in the United States as a whole.
Comparison to previous study
The population-based estimate of 50 000-93 000 patients per year with nonrevascularizable angina after bypass is the first estimate of its kind. Mukherjee et al. [4] reviewed 500 patients with known or suspected CAD undergoing coronary angiography between January and May 1998. They concluded that 59 symptomatic patients (12%) were not suitable for PCI or CABG. Extrapolation to the US population yielded a range of 100 000-200 000 patients per year. The estimate quoted was calculated as a percentage of all patients that underwent coronary angiography in 1996 regardless of clinical indication. The vast majority of patients reviewed (83%) were tertiary referrals and, therefore, did not reflect a communitybased estimate [4] . It must be stated that the above study had broader inclusion criteria than our study, which included only post-coronary artery bypass patients. Data from the Third National Health and Nutrition Examination Survey estimates 300 000-900 000 patients in the United States have refractory angina, and 25 000-75 000 new cases are diagnosed annually [2] .
Comparisons with earlier studies must consider that the range of 50 000-93 000 nonrevascularizable post-coronary bypass patients per year in this study certainly underestimates the entire nonrevascularizable population as some of such patients will not have had previous bypass. Furthermore, not all post-coronary bypass patients with angina will undergo coronary and graft angiography in the 'real world'. However, the vast majority of (85-95%) patients enrolled in prospective studies such as the Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis Trial [5] and the Fibroblast Growth Factor Initiating Revascularization Trial [6] , which enrolled the so-called 'no option' angina patients, had previous CABG performed. These estimates must be considered when defining the ultimate need for new therapies as well as the effort and time needed to recruit such patients for clinical trials, particularly given the high number of comorbidities.
Outcomes
The lack of difference in all-cause and cardiac mortality between the group of patients receiving further revascularization and those that did not over the follow-up period is notable. Patients with a history of remote CABG pose numerous challenges when they develop angina as progression of native CAD leaves fewer options for redo CABG, and graft attrition diminishes the chances for successful PCI. Brener et al. [8] demonstrated that revascularization in post-coronary bypass patients is associated with poor long-term outcome with a mortality rate of 25% at 5 years. The method of repeat revascularization has little to do with long-term mortality [9] . It must be remembered that patients included in our study are frequently at high risk with significant comorbidities, very distinct from the risk factor profile of patients enrolled in randomized controlled trials. Of note, approximately 68% of our nonrevascularizable population had a severely degenerated graft as one of the determinants of their nonsuitability for further revascularization. The periprocedural and 6-month outcomes of percutaneous interventions to vein grafts using distal embolic protection devices are indeed improving [10] . High-risk features of vein grafts for PCI, which included diffusely diseased grafts over 8 years and coexistent severe distal disease beyond the graft insertion precluded many of our patients from invasive treatment. Currently, there are no published data on symptomatic post-coronary bypass patients treated with medical treatment versus surgical or percutaneous revascularization. However, when patients present with symptomatic multivessel CAD after CABG, the choice of revascularization method or lack of revascularization is dictated mostly by anatomical considerations [8] .
The subgroup analysis is also interesting in that 92 patients were classified as nonrevascularizable based on anatomical and technical criteria after angiographic analysis. The remaining 78 patients despite having chronic angina and presence of ischemia were deemed not to require further PCI or surgical intervention after angiographic assessment. Theoretically, these patients may be experiencing angina from impaired coronary flow reserve secondary to microvascular ischemia. Consideration of these patients furthers the spectrum of nonrevascularizability in terms of macrovascular and microvascular nonrevascularizable CAD.
Limitations
Our study has several limitations. The racial and ethnic composition of Olmsted County limits generalizability to other groups. The Olmsted County population is predominantly white Caucasian with 10.8% of the population greater than 65 years old. However, no regional population can be representative of the United States as a whole, as illustrated by the known regional variations in heart disease rates. To this end, however, it should be underscored that Olmsted County cardiovascular disease trends parallel national trends, thus supporting the generalizability of our data [11] . The adjusted incidence of coronary artery bypass surgery at the Mayo Clinic on Olmsted County patients from 2001 to 2005, was 145.8 per 100 000 population. This is an important fact to take into account in relation to the United States as a whole. It must be stated that the selection of post-coronary bypass patients was nonrandomized but included all patients from Olmsted County with angina undergoing coronary and graft angiography. This rate of postbypass coronary angiography will have an impact on our incidence of nonrevascularizable CAD, but we feel it reflects the current modern management of angina and coronary ischemia in the post-CABG patient. It must be also stated that this study reflects nonrevascularizable CAD in relation to the post-CABG population, and therefore projection of these results to patients without previous CABG is not possible. The ability to detect differences in outcomes between the groups is attenuated by the small numbers in the study.
Conclusion
We estimate a population-based adjusted incidence of patients with postbypass nonrevascularizable angina of 17.9-33.2 per 100 000 adjusting for age and sex differences between the Olmsted County population and the US white 2000 population. This equates to approximately 50 000 (95% CI: 40 000-61 000) to 93 000 (95% CI: 79 000-110 000) cases per year in the United States as a whole. We found no significant difference in all-cause mortality or cardiac mortality between the group that underwent further revascularization and those that did not. Such patients may be candidates for novel or investigational therapies. Further epidemiologic research characterizing the incidence and prevalence of advanced, symptomatic nonrevascularizable CAD is needed.
